YI

BEARISH

$6.83 Live

111, Inc. · NASDAQ

$2.48 52W Range $11.17

YI 111, Inc. - Fundamental Analysis

BEARISH

Console Chart News

YI Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Medical Distribution

Current Price Live

$6.83

52W High

$11.17

52W Low

$2.48

Overview AI Snowflake Price Valuation Profitability Growth Health Peers SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 24, 2026

Market cap

$59.2M

P/E

N/A

ROE

-7.6%

Profit margin

-0.5%

Debt/Equity

1.01

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

YI presents a high-risk profile characterized by a stable Piotroski F-Score (5/9) that masks severe underlying fundamental decay. The most critical red flag is a negative Price/Book ratio (-0.60), indicating negative shareholders' equity and potential insolvency. This is compounded by a significant revenue contraction of -26.70% YoY and a poor Quick Ratio of 0.45, suggesting severe liquidity constraints. Despite a speculative 6-month price bounce, the lack of analyst coverage and bearish technical trend (0/100) suggest a lack of institutional support.

Key Strengths

Piotroski F-Score of 5/9 indicates stable short-term financial health

Operating margin is nearly at break-even (-0.01%)

Recent 6-month price recovery (+53.5%) shows speculative interest

Debt/Equity ratio (1.01) is lower than the healthcare sector average (2.80)

Current ratio (1.09) remains slightly above 1.0

Key Risks

Negative shareholders' equity as indicated by Price/Book of -0.60

Severe revenue decline (-26.70% YoY and -16.66% Q/Q)

Poor liquidity with a Quick Ratio of 0.45

Micro-cap status ($0.06B) leads to extreme volatility

High Forward P/E (48.79) is unjustifiable given shrinking revenues

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

High Risk / Speculative

Key drivers: Negative Book Value, Revenue Contraction, Liquidity Risk

Confidence

90%

Value

10/100

Graham Number unavailable due to negative equity; P/B of -0.60 is a critical failure.

Positives

No standout positives identified.

Watchpoints

Negative P/B ratio
High Forward P/E relative to growth

Future

15/100

Consistent revenue decline suggests a failing business model or loss of market share.

Positives

No standout positives identified.

Watchpoints

YoY Revenue Growth -26.70%
Q/Q Revenue Growth -16.66%

Past

40/100

Long-term trend is negative despite a mid-term spike.

Positives

3Y Change +149.3%

Watchpoints

5Y Change -44.7%
1Y Change -18.9%

Health

45/100

Piotroski score is stable, but the balance sheet is fundamentally broken (negative equity).

Positives

Piotroski F-Score 5/9

Watchpoints

Negative Equity
Low Quick Ratio (0.45)

Dividend

0/100

Non-dividend paying growth/distressed stock.

Positives

No standout positives identified.

Watchpoints

No dividend paid
0/100 strength score

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$6.83

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for YI and closest competitors.

Updated 2026-04-23

Company	5Y	3Y	1Y	6M	1M	1W
YI 111, Inc. Primary	-44.7%	+149.3%	-18.9%	+53.5%	+7.4%	+2.4%
MDAI Spectral AI, Inc. Peer	-81.1%	-87.0%	+48.0%	-16.3%	+40.1%	+11.4%
LUNG Pulmonx Corporation Peer	-96.7%	-86.8%	-73.4%	-9.4%	-14.3%	+5.9%
PAVM PAVmed Inc. Peer	-99.5%	-95.5%	-55.3%	-38.4%	-12.3%	-6.5%
DCGO DocGo Inc. Peer	-94.3%	-93.1%	-77.6%	-55.1%	-15.2%	-9.4%

111, Inc.

Primary

-44.7%

+149.3%

-18.9%

+53.5%

+7.4%

+2.4%

MDA

Spectral AI, Inc.

Peer

-81.1%

-87.0%

+48.0%

-16.3%

+40.1%

+11.4%

LUN

Pulmonx Corporation

Peer

-96.7%

-86.8%

-73.4%

-9.4%

-14.3%

+5.9%

PAV

PAVmed Inc.

Peer

-99.5%

-95.5%

-55.3%

-38.4%

-12.3%

-6.5%

DCG

DocGo Inc.

Peer

-94.3%

-93.1%

-77.6%

-55.1%

-15.2%

-9.4%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

48.79

N/A

-0.6

0.0

0.14

121.33

$59.2M

Profitability

Profit margins and return metrics

Profit Margin -0.53%

Operating Margin -0.01%

Gross Margin 3.01%

ROE -7.57%

ROA -0.06%

Growth

Revenue and earnings growth rates

Revenue Growth -26.7%

Earnings Growth N/A

Q/Q Revenue Growth -16.66%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

1.01

Moderate

Current Ratio

1.09

Good

Quick Ratio

0.45

Poor

Cash/Share

$3.2

Quarterly Earnings History

EPS performance vs analyst estimates

2026-03-19

$N/A

Healthcare Sector Comparison

Comparing YI against 528 companies in the Healthcare sector (28 bullish, 156 neutral, 344 bearish)

Return on Equity (ROE)

-7.57%

This Stock

-92.94%

Sector Avg

-91.9% (Below Avg)

Profit Margin

-0.53%

This Stock

-16.56%

Sector Avg

-96.8% (Weaker)

Debt to Equity

1.01

This Stock

2.75

Sector Avg

-63.1% (Less Debt)

Revenue Growth

-26.7%

This Stock

131.76%

Sector Avg

-120.3% (Slower)

Current Ratio

1.09

This Stock

4.62

Sector Avg

-76.5% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
YI 111, Inc.	BEARISH	$59.2M	-	-7.6%	-0.5%	$6.83
MDAI Spectral AI, Inc.	BEARISH	$58.87M	-	-%	-38.5%	$1.85	Compare
LUNG Pulmonx Corporation	BEARISH	$60.82M	-	-77.2%	-59.7%	$1.44	Compare
PAVM PAVmed Inc.	BEARISH	$57.53M	-	-32.3%	564.8%	$9.11	Compare
DCGO DocGo Inc.	BEARISH	$56.28M	-	-89.0%	-56.6%	$0.57	Compare

YI 111, Inc.

BEARISH

Mkt Cap

$59M

P/E

ROE

-7.6%

Price

$6.83

MDAI Spectral AI, Inc.

Compare with YI

LUNG Pulmonx Corporation

Compare with YI

Compare with YI

Compare with YI

SEC Filings

Recent regulatory filings from the SEC EDGAR database

20-F

2025-04-29

YI filed its 20-F annual report on April 29, 2025, providing a comprehensive overview of its fiscal year financial performance. The filing details the company's financial highlights and outlines the primary operational and market risks facing the business.

20-F

FORM 20-F

2024-05-14

YI filed its Form 20-F annual report on May 14, 2024. Specific financial highlights and risk factors cannot be detailed as no excerpts were provided alongside the filing metadata.

Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning YI from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

YI

YI 111, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

SEC Filings

Past News Coverage

Wait — Don't Miss Out!